Articles from Juniper Biosciences

BEDMINSTER, N.J., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Juniper Biosciences ("Juniper" or "the Company"), a radiopharmaceutical drug development company, today announced the establishment of its clinical team with the appointments of Deepak Behera, M.D., as Chief Medical Officer and Javed Mahmood, D.D.S., Ph.D., as Senior Director of Clinical Development. Together, they will lead clinical development across Juniper's pipeline, including JBS-003 (18F-fluoromisonidazole, or FMISO), which is in a Phase 3 clinical trial and has received FDA Breakthrough Therapy Designation. The Company also announced the build-out of its commercial organization with the appointment of Robert Sgroi as Chief Commercial Officer, as it prepares for potential launches of its two late-stage diagnostic programs, JBS-002 and JBS-004.

Prostate cancer and Alzheimer’s disease imaging programs position the Company for FDA submissions in 2027 across two of the fastest-growing segments in molecular imaging

BEDMINSTER, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Juniper Biosciences today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to JBS-003 (18F-fluoromisonidazole, or FMISO), the first-in-class hypoxia tracer in the U.S., for the identification of tumor hypoxia to guide de-escalated radiation therapy in patients with HPV-positive Oropharyngeal Carcinoma (OPC). JBS-003, licensed from Memorial Sloan Kettering Cancer Center (MSK), is the cornerstone of a new precision oncology paradigm designed to spare patients from the devastating side effects of high-dose radiation therapy. As a leader in molecular imaging, MSK pioneered the use of hypoxia tracers to overcome the limitations of traditional imaging.

BRIDGEWATER, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Juniper Biosciences, a cutting-edge radiopharmaceutical drug development company, today announced the launch of its Scientific Advisory Board (SAB) and the appointment of Jason S. Lewis, Ph.D., as its inaugural Chair. Dr. Lewis, a world-renowned leader in molecular imaging and radiochemistry, will lead a multidisciplinary group of experts to guide the clinical and strategic development of Juniper’s precision oncology pipeline.

BRIDGEWATER, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Juniper Biosciences today announced a strategic licensing agreement with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the development of JBS-003 (18F-fluoromisonidazole, or FMISO). This first-in-class hypoxia tracer in the U.S. is the cornerstone of a new precision oncology paradigm designed to spare patients from the devastating side effects of high-dose radiation therapy.

Financing co-led by NovaCapital, private high-net-worth individuals and members of Club Degli Investitori